Here is another paper showing that active AFP causes the shift from M1 to Mw : Zhang M, Liu K, Zhang Q, Xu J, Liu J, Lin H, Lin B, Zhu M, Li M. Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells. Front Immunol. 2023 Feb 23;14:1081572. doi: 10.3389/fimmu.2023.1081572.
In the Patterson protocol which seems to have worked well in 18 PASC patients [Patterson BK, Yogendra R, Guevara-Coto J, Mora-Rodriguez RA, Osgood E, Bream J, Parikh P, Kreimer M, Jeffers D, Rutland C, Kaplan G, Zgoda M. Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Front Med (Lausanne). 2023 Feb 8;10:1122529. doi: 10.3389/fmed.2023.1122529.] statins are combined with maraviroc (CCR5 antagonist). Apparently maraviroc may be a potent AFP antagonist according to this paper [Kimberly JA et al., Mitochondrial dysfunction reactivates alpha-fetoprotein expression that drives copper-dependent immunosuppression in mitochondrial disease models. J Clin Invest January 3, 2023; 133 (1): e154684 https://doi.org/ 10.1172/JCI154684.] where they state
“Dysfunctional mitochondria induces AFP that with copper activates cell death in CD8 T cells by interacting with CCR5.” Accordingly AFP antagonists would likely reverse the loss of CD8 T cells associated with PASC as well as chronic fatigue syndrome as has been reported by Dr. Patterson’s group. (NB: Copper activates AFP while zinc inactivates AFP). Many papers have reported that maraviroc causes M2 macrophages to revert back to the protective M1. So while this promising Patterson protocol seems to validate Image 1, the second component, statin which may block M0 to M1 is perhaps unexpected. However, it seems it may be necessary to start the reversion of endothelial inflammation. For example, perhaps one has to stop the main pathogenic effect of S1 protein by eliminating its target (CD14+CD16+ intermediate monocytes). On the other hand, Patterson states statins reduce inflammation of endothelial cells as does maraviroc. Patterson reminds us that PASC does not involve replication competent SARS-CoV-2 so that the selective and short term use of 'anti-inflammatories' for 6 weeks may not be as deleterious to the host as one might expect. So the use of anti-inflammatories may be needed for recovery from PASC but we need to be selective about which ones.
While the I recover protocols do not have curcumin, the early treatment of COVID-19 still does along with 5 to 10 mg of melatonin. They are anti-inflammatories that may enhance ISM putting the patient at higher risk of COVID-19 severity (ie., may increase hypertension, a well known risk factor for COVID-19 severity). Interestingly, they have added a pharmaceutical drug, Probenecid to their protocol which treats hypertension. Wonder if they would have better results without curcumin and melatonin???
The I recover vax injury protocol is very good and only suggests low-dose corticosteroids (GCs) as the third line of therapy which is probably a good idea. However aspirin, melatonin (> 2 mgs) and resveratrol are anti-inflammatories and could block recovery. In 26 years of the reversion of immunosenescence of macrophages (ISM at Immune System Management in Ottawa) to reestablish wellness in clients, no GCs were used. However, aspirin, melatonin (> 2 mgs), and resveratrol (but the worst were statins and curcumin) all impeded the ability to achieve recovery (takes about 3 months to see initial improvements). Just saying there is good clinical evidence to avoid immunosuppressive anti-inflammatories (that do not correct hypertension), along with the theoretical basis for the proposed protocol. I will modify to put the MP as a second or third line of therapy. Thanks.
I attend their webinars and cc them on all my tweets. I subscribe to all their tweets. I have contributed to their upcoming book. No I do not call them but maybe I should.
Thank You again, Dr. Laderoute. The revision is much clearer.
Here is another paper showing that active AFP causes the shift from M1 to Mw : Zhang M, Liu K, Zhang Q, Xu J, Liu J, Lin H, Lin B, Zhu M, Li M. Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells. Front Immunol. 2023 Feb 23;14:1081572. doi: 10.3389/fimmu.2023.1081572.
In the Patterson protocol which seems to have worked well in 18 PASC patients [Patterson BK, Yogendra R, Guevara-Coto J, Mora-Rodriguez RA, Osgood E, Bream J, Parikh P, Kreimer M, Jeffers D, Rutland C, Kaplan G, Zgoda M. Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Front Med (Lausanne). 2023 Feb 8;10:1122529. doi: 10.3389/fmed.2023.1122529.] statins are combined with maraviroc (CCR5 antagonist). Apparently maraviroc may be a potent AFP antagonist according to this paper [Kimberly JA et al., Mitochondrial dysfunction reactivates alpha-fetoprotein expression that drives copper-dependent immunosuppression in mitochondrial disease models. J Clin Invest January 3, 2023; 133 (1): e154684 https://doi.org/ 10.1172/JCI154684.] where they state
“Dysfunctional mitochondria induces AFP that with copper activates cell death in CD8 T cells by interacting with CCR5.” Accordingly AFP antagonists would likely reverse the loss of CD8 T cells associated with PASC as well as chronic fatigue syndrome as has been reported by Dr. Patterson’s group. (NB: Copper activates AFP while zinc inactivates AFP). Many papers have reported that maraviroc causes M2 macrophages to revert back to the protective M1. So while this promising Patterson protocol seems to validate Image 1, the second component, statin which may block M0 to M1 is perhaps unexpected. However, it seems it may be necessary to start the reversion of endothelial inflammation. For example, perhaps one has to stop the main pathogenic effect of S1 protein by eliminating its target (CD14+CD16+ intermediate monocytes). On the other hand, Patterson states statins reduce inflammation of endothelial cells as does maraviroc. Patterson reminds us that PASC does not involve replication competent SARS-CoV-2 so that the selective and short term use of 'anti-inflammatories' for 6 weeks may not be as deleterious to the host as one might expect. So the use of anti-inflammatories may be needed for recovery from PASC but we need to be selective about which ones.
Thank You, Dr. Laderoute.
It is very difficult to get helpful direction in treating this now common, but forbidden-to-mention chronically impairing medical condition.
;-(
This is the base-resource for medical practitioners: https://covid19criticalcare.com/protocol/i-recover-post-vaccine-treatment/
While the I recover protocols do not have curcumin, the early treatment of COVID-19 still does along with 5 to 10 mg of melatonin. They are anti-inflammatories that may enhance ISM putting the patient at higher risk of COVID-19 severity (ie., may increase hypertension, a well known risk factor for COVID-19 severity). Interestingly, they have added a pharmaceutical drug, Probenecid to their protocol which treats hypertension. Wonder if they would have better results without curcumin and melatonin???
i-Recover does advocate melatonin in the first-line cocktail.
The I recover vax injury protocol is very good and only suggests low-dose corticosteroids (GCs) as the third line of therapy which is probably a good idea. However aspirin, melatonin (> 2 mgs) and resveratrol are anti-inflammatories and could block recovery. In 26 years of the reversion of immunosenescence of macrophages (ISM at Immune System Management in Ottawa) to reestablish wellness in clients, no GCs were used. However, aspirin, melatonin (> 2 mgs), and resveratrol (but the worst were statins and curcumin) all impeded the ability to achieve recovery (takes about 3 months to see initial improvements). Just saying there is good clinical evidence to avoid immunosuppressive anti-inflammatories (that do not correct hypertension), along with the theoretical basis for the proposed protocol. I will modify to put the MP as a second or third line of therapy. Thanks.
Thank You, Dr. Laderoute. Are you in touch with Pierre Kory MD, or others at the FLCCC?
I know that he and they seek to keep their recommendations updated, and always seek to improve them where possible.
I attend their webinars and cc them on all my tweets. I subscribe to all their tweets. I have contributed to their upcoming book. No I do not call them but maybe I should.
Thanks.